Mr Skolnik was previously a managing director in the health care group at Piper Jaffray & Company. Prior to joining Piper Jaffray, where he was a founding member of the company’s New York banking office, Mr Skolnik held positions in the health care groups of SG Cowen Securities and Cowen & Company.
Mr Skolnik holds an MBA in finance from Columbia University and a BS in mechanical engineering from Lehigh University.
Ulrich Grau, president and CEO of Lux Biosciences, said: “Mr Skolnik’s many years of experience and his network in the financial community will serve our company well as our first products complete Phase III clinical development and our company enters its next stage of growth.”